MR 20492 and MR 20494: two indolizinone derivatives that strongly inhibit human aromatase.

This research revolves around the synthesis of two new indolizinone derivatives – MR 20492 and MR 20494, which are effective in inhibiting the function of human aromatase, a key enzyme in the biosynthesis of estrogen. These findings could have significant implications for developing therapies to treat estrogen-dependent cancers.

Synthesis and Testing of Indolizinone Derivatives

• The researchers synthesized a new set of indolizinone derivatives, designed specifically to fit and interact with an extrahydrophobic pocket within the active site of the aromatase enzyme. MR 20492 and MR 20494 were identified as possessing strong inhibitory properties against human aromatase.
• Equine aromatase, another variant of the enzyme that’s well studied, was used as a comparative model. The research points out structural differences between active sites of human and equine aromatases based on the attainable Ki/Km values.
• Ki/Km (the ratio of reaction constants) provides a measure of the efficiency of enzyme inhibition. The lower the Ki/Km value, the more effective is the inhibition. MR 20492 and MR 20494 demonstrated lower Ki/Km values compared to other known inhibitors like 4-hydroxyandrostenedione and MR 20814, indicating more potent inhibitory action.

Study on Interaction and Enzyme Inhibition

• Further investigation into spectrum studies revealed that MR 20492 and MR 20494 displayed a combination of type-I and -II spectra with both enzymes, suggestive of isomerization (rearrangement of a molecule) in polar solvent.
• Unlike some previously studied inhibitors, these newly synthesized compounds do not inactivate the enzyme, which is beneficial for specific inhibition without affecting overall enzymatic functionality.

Impacts on Cell Cultures and Prospective Treatments

• Tests on aromatase activity in transfected 293 cell cultures proved a strong inhibition, without any cytotoxicity in Hela cells, making these compounds potential therapeutic agents for treating estrogen-dependent cancers.
• The study elucidates that these new molecules could not only serve as potential drugs but also as tools for understanding the structure and the function of the aromatase active site – insights that could be instrumental in the development and optimization of future treatments.